Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed)....
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika...
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and...
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30,...
Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
Emergent BioSolutions Inc. (NYSE: EBS) today announced, through its subsidiary Adapt Pharma, the launch of two new programs to raise public awareness of the potential risks of opioids and the...
Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN® (naloxone HCl) Nasal Spray, the first and only intranasal...
Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent...
Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that...
Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC
Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers...
Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire Adapt Pharma and its flagship product NARCAN® (naloxone HCl) Nasal Spray, the first and only...
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the third quarter and...
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will...